Revance Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>RT</div>
RVNC -- USA Stock  

USD 24.79  0.28  1.14%

Revance Therapeutics Revenue Per Employee is projected to decrease significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 2,140. The current year Average Equity is expected to grow to about 201.6 M, whereas Net Income Per Employee is forecasted to decline to (891.3 K). The essential aim of this article is to break down our current position on Revance for investors considering to short it. We will analyze why Revance Therapeutics investors may still consider a stake in the business.
Published over three weeks ago
View all stories for Revance Therapeutics | View All Stories
Are Revance (NASDAQ:RVNC) investors starting to hold back?
Revance Therapeutics has a beta of -0.4605. Let's try to break down what Revance's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Revance Therapeutics will likely underperform. The beta indicator helps investors understand whether Revance Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Revance deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Revance Therapeutics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Revance Therapeutics


How important is Revance Therapeutics's Liquidity

Revance Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Revance Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Revance Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Revance Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Revance Therapeutics, but it might be worth checking our own buy vs. sell analysis

Revance Therapeutics exotic insider transaction detected

Legal trades by Revance Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Revance insider trading alert for general transaction of common stock by Rankin Aubrey, President Innovation & Tech, on 30th of October 2020. This event was filed by Revance Therapeutics Inc with SEC on 2020-10-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Revance Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Revance Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Revance Therapeutics future alpha.

Returns Breakdown

Return on Investment(95.63)
Return on Assets(60.72)
Return on Equity(92.71)
Return Capital(0.69)
Return on Sales(346.95)

Revance Therapeutics is epected to finish above $25 in December

Current Sortino Ratio is up to 0.05. Price may slip again. Revance Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Revance Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Revance Therapeutics future alpha.

Our Final Take On Revance Therapeutics

Whereas other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Revance Therapeutics may offer a potential longer-term growth to investors. To conclude, as of the 1st of November 2020, our up-to-date 30 days Buy-Hold-Sell recommendation on the company is Strong Sell. However, we believe Revance Therapeutics is undervalued with below average odds of financial turmoil for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Revance Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com